3-(2-dimethyl-aminoethyl)-5-(n-nonyl)-2-(pyridin-3-yl)thiazolidin-4-one | 119384-25-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(2-dimethyl-aminoethyl)-5-(n-nonyl)-2-(pyridin-3-yl)thiazolidin-4-one
• 英文别名: 3-(2-dimethyl-aminoethyl)-5-(n-nonyl)-2-(3-pyridyl)thiazolidin-4-one；3-(2-Dimethylaminoethyl)-5-(n-nonyl)-2-(3-pyridyl)thiazolidin-4-one；3-[2-(dimethylamino)ethyl]-5-nonyl-2-pyridin-3-yl-1,3-thiazolidin-4-one
• CAS: 119384-25-7
• 化学式: C₂₁H₃₅N₃OS
• 分子量: 377.594
• InChiKey: VVQOQLSAGZXRBH-UHFFFAOYSA-N

物化性质

• 沸点：
  530.1±50.0 °C(Predicted)
• 密度：
  1.036±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  26
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  61.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-(4-chlorophenyl)-3-methyl-2-(3-pyridyl)-thiazolidin-4-one 生成 3-(2-dimethyl-aminoethyl)-5-(n-nonyl)-2-(pyridin-3-yl)thiazolidin-4-one
  参考文献：
  名称：

  Certain pyridyl-thiazolidin-4-one having anti-ulcer activity

  摘要：

  一种由以下式表示的2-吡啶基噻唑啉-4-酮衍生物：其中R.sub.1和R.sub.2分别为氢原子、C.sub.1-C.sub.20烷基、C.sub.2-C.sub.20烯基、C.sub.2-C.sub.20炔基、芳基、C.sub.3-C.sub.8环烷基或可能具有取代基的芳基烷基，R.sub.3为氢原子、C.sub.1-C.sub.20烷基、C.sub.2-C.sub.20烯基、C.sub.2-C.sub.20炔基、C.sub.3-C.sub.8环烷基或可能具有取代基的芳基烷基，P为吡啶基或其可能具有取代基的N-取代吡啶盐基，所述取代基选自卤原子、氰基、羟基、氨基、低烷基、低烷氧基、低烷基氨基、卤代低烷基、酰基、酰氧基、硫代酰基、酰胺基、羧基、低烷氧羰基、氨基甲酰基、低烷基取代的氨基甲酰基、杂环基和低环烷基，n表示0、1或2的整数，或其药学上可接受的盐，以及作为有效成分的抗溃疡药物，包含上述2-吡啶基噻唑啉-4-酮衍生物或其药学上可接受的盐。

  公开号：

  US05021435A1

文献信息

• Thiazolidin-4-one derivatives useful for treating diseases caused by
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US04992455A1

  公开（公告）日：1991-02-12

  Thiazolidin-4-one derivative represented by the folowing general formula (I) and acid addition salts thereof ##STR1## wherein; R.sup.1 and R.sup.2 are the same or different and denote each (i) a residue represented by the general formula --A--R.sup.4 wherein, A denotes a single bond, C.sub.1 -C.sub.8 alkylene, C.sub.2 -C.sub.8 alkenylene, or C.sub.2 -C.sub.8 alkynylene and R.sup.4 denotes hydrogen, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.1 -C.sub.6 haloalkyl, or (ii) a residue represented by the general formula (CH.sub.2).sub.n O}.sub.m (CH.sub.2).sub.n' O}B--R.sup.5 wherein, B denotes a single bond or C.sub.1 -C.sub.6 alkylene, R.sup.5 denotes hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, substituted silyl, or substituted or unsubstituted aryl, n and n' denote each an integer of 2 to 4, m denotes an integer of 1 to 3, and m' denotes an integer of 0 to 2; and R.sup.3 denotes hydrogen, C.sub.1 -C.sub.2 alkyl, allyl, 2-propynyl, or a residue represented by (a) the general formula --CH.sub.2).sub.l R.sup.6 wherein, R.sup.6 denotes halogen, an aryl group substituted or unsubstituted by one or more hydroxy or C.sub.1 -C.sub.4 alkoxy groups, or a residue represented by the general formula --D--R.sup.7 (D denotes oxygen or sulfur and R.sup.7 denotes hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkanol) and l denotes an integer of 2 to 4, (b) the general formula --CH.sub.2).sub.k CO--E--R.sup.8 wherein, E denotes oxygen, sulfur, imino, or C.sub.1 -C.sub.4 alkylimino, R.sup.8 denotes hydrogen or C.sub.1 -C.sub.4 alkyl, or --(E--R.sup.8) denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms, and k denotes an integer of 1 to 3, or (c) the general formula --F--R.sup.9 wherein, F denotes C.sub.2 -C.sub.6 alkylene and R.sup.9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula ##STR2## (R.sup.10 denotes hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkyl or R.sup.10 in combination with R.sup.11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms), with the proviso that, when R.sup.1 is hydrogen and R.sup.2 is methyl, R.sup.3 denotes hydrogen, C.sub.1 -C.sub.2 alkyl, 2-propynyl, or a residue represented by (a) the general formula --CH.sub.2).sub.l R.sup.6 wherein, R.sup.6 denotes halogen, an aryl group substituted or unsubstituted by one or more hydroxy or C.sub.1 -C.sub.4 alkoxy groups, or a residue represented by the general formula --D--R.sup.7 (D denotes oxygen or sulfur and R.sup.7 denotes hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkanoyl) and l denotes an integer of 2 to 4, (b) the general formula --CH.sub.2).sub.k CO--E--R.sup.8 wherein, E denotes oxygen, sulfur, imino, or C.sub.1 -C.sub.4 alkylimino, R.sup.8 denotes hydrogen or C.sub.1 -C.sub.4 alkyl, or --(E--R.sup.8) denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms, and k denotes an integer of 1 to 3, or (c) the general formula --F--R.sup.9 wherein, F denotes C.sub.2 -C.sub.6 alkylene and R.sup.9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula ##STR3## (R.sup.10 denotes hydrogen, C.sub.2 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkanoyl and R.sup.11 denotes hydrogen or C.sub.1 -C.sub.4 alkyl or R.sup.10 in combination with R.sup.11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms. Having selective PAF-antagonistic activities, these compounds are very useful as preventive and curative agents for PAF-induced diseases, for example, various kinds of inflammation, allergic diseases, circulatory diseases, and gastro-intestinal diseases.

  硫唑啉-4-酮衍生物由以下一般式（I）和其酸盐表示： 其中；R.sup.1和R.sup.2相同或不同，各自表示（i）由一般式--A--R.sup.4表示的残基，其中，A表示单键，C.sub.1 -C.sub.8烷基，C.sub.2 -C.sub.8烯基，或C.sub.2 -C.sub.8炔基，R.sup.4表示氢，C.sub.1 -C.sub.12烷基，C.sub.2 -C.sub.8烯基，C.sub.3 -C.sub.8环烷基，或C.sub.1 -C.sub.6卤代烷基，或（ii）由一般式(CH.sub.2).sub.n O}.sub.m (CH.sub.2).sub.n' O}B--R.sup.5表示的残基，其中，B表示单键或C.sub.1 -C.sub.6烷基，R.sup.5表示氢，C.sub.1 -C.sub.6烷基，C.sub.2 -C.sub.8烯基，C.sub.3 -C.sub.8环烷基，取代硅基，或取代或未取代芳基，n和n'各自表示2至4的整数，m表示1至3的整数，m'表示0至2的整数；R.sup.3表示氢，C.sub.1 -C.sub.2烷基，烯丙基，2-丙炔基，或由（a）一般式--CH.sub.2).sub.l R.sup.6表示的残基，其中，R.sup.6表示卤素，一个或多个羟基或C.sub.1 -C.sub.4烷氧基取代或未取代的芳基，或由一般式--D--R.sup.7（D表示氧或硫，R.sup.7表示氢，C.sub.1 -C.sub.4烷基，或C.sub.1 -C.sub.4烷醇基）表示的残基，l表示2至4的整数，（b）一般式--CH.sub.2).sub.k CO--E--R.sup.8表示的残基，其中，E表示氧，硫，亚胺，或C.sub.1 -C.sub.4烷基亚胺，R.sup.8表示氢或C.sub.1 -C.sub.4烷基，或--(E--R.sup.8)表示一个含其他杂原子的5-到7-成员环氨基基团，k表示1至3的整数，或（c）一般式--F--R.sup.9表示的残基，其中，F表示C.sub.2 -C.sub.6烷基，R.sup.9表示含氮的杂环芳基残基或由一般式表示的氨基基团##STR2##（R.sup.10表示氢，C.sub.1 -C.sub.4烷基，或C.sub.1 -C.sub.4烷基或R.sup.10与R.sup.11的组合表示含其他杂原子的5-到7-成员环氨基基团），但是，当R.sup.1为氢且R.sup.2为甲基时，R.sup.3表示氢，C.sub.1 -C.sub.2烷基，2-丙炔基，或由（a）一般式--CH.sub.2).sub.l R.sup.6表示的残基，其中，R.sup.6表示卤素，一个或多个羟基或C.sub.1 -C.sub.4烷氧基取代或未取代的芳基，或由一般式--D--R.sup.7（D表示氧或硫，R.sup.7表示氢，C.sub.1 -C.sub.4烷基，或C.sub.1 -C.sub.4醯基）表示的残基，l表示2至4的整数，（b）一般式--CH.sub.2).sub.k CO--E--R.sup.8表示的残基，其中，E表示氧，硫，亚胺，或C.sub.1 -C.sub.4烷基亚胺，R.sup.8表示氢或C.sub.1 -C.sub.4烷基，或--(E--R.sup.8)表示一个含其他杂原子的5-到7-成员环氨基基团，k表示1至3的整数，或（c）一般式--F--R.sup.9表示的残基，其中，F表示C.sub.2 -C.sub.6烷基，R.sup.9表示含氮的杂环芳基残基或由一般式表示的氨基基团##STR3##（R.sup.10表示氢，C.sub.2 -C.sub.4烷基或C.sub.1 -C.sub.4醯基，R.sup.11表示氢或C.sub.1 -C.sub.4烷基或R.sup.10与R.sup.11的组合表示含其他杂原子的5-到7-成员环氨基基团。这些化合物具有选择性PAF拮抗活性，对于PAF诱导的疾病，例如各种炎症、过敏性疾病、循环系统疾病和胃肠道疾病的预防和治疗非常有用。
• Thiazolidin-4-one derivatives and acid addition salts thereof useful for
  申请人：Sumitomo Chemical Company, Limited

  公开号：US05106860A1

  公开（公告）日：1992-04-21

  Thiazolidin-4-one derivative represented by the following general formula (I) and acid addition salts thereof ##STR1## wherein; R.sup.1 and R.sup.2 are the same or different and denote each (i) a residue represented by the general formula --A--R.sup.4 wherein, A denotes a single bond, C.sub.1 -C.sub.8 alkylene, C.sub.2 -C.sub.8 alkenylene, or C.sub.2 -C.sub.8 alkynylene and R.sup.4 denotes hydrogen, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.1 -C.sub.6 haloalkyl,or (ii) a residue represented by the general formula ##STR2## wherein, B denotes a single bond or C.sub.1 -C.sub.6 alkylene, R.sup.5 denotes hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, substituted silyl, or substituted or unsubstituted aryl, n and n' denote each an integer of 2 to 4, m denotes an integer of 1 to 3, and m' denotes an integer of 0 to 2; R.sup.3 denotes hydrogen, C.sub.1 -C.sub.2 alkyl, allyl, 2-propynyl, or (c) the general formula --F--R.sup.9 wherein, F denotes C.sub.2 -C.sub.6 alkylene and R.sup.9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula ##STR3## (R.sup.10 denotes hydrogen, C.sub.2 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkanoyl and R.sup.11 denotes hydrogen or C.sub.1 -C.sub.4 alkyl or R.sup.10 in combination with R.sup.11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms. Having selective PAF-antagonistic activities, these compounds are very useful as preventive and curative agents for PAF-induced diseases, for example, various kinds of inflammation, allergic diseases, circulatory diseases, and gastro-intestinal diseases.

  以下是由下列一般式（I）表示的噻唑烷-4-酮衍生物及其酸加成盐：##STR1## 其中，R.sup.1和R.sup.2相同或不同，分别表示（i）由一般式--A--R.sup.4表示的残基，其中，A表示单键，C.sub.1-C.sub.8烷基，C.sub.2-C.sub.8烯基或C.sub.2-C.sub.8炔基，而R.sup.4表示氢，C.sub.1-C.sub.12烷基，C.sub.2-C.sub.8烯基，C.sub.3-C.sub.8环烷基或C.sub.1-C.sub.6卤代烷基；或（ii）由下列一般式表示的残基：##STR2## 其中，B表示单键或C.sub.1-C.sub.6烷基，R.sup.5表示氢，C.sub.1-C.sub.6烷基，C.sub.2-C.sub.8烯基，C.sub.3-C.sub.8环烷基，取代硅烷基或取代或未取代芳基，n和n'分别表示2到4的整数，m表示1到3的整数，而m'表示0到2的整数；R.sup.3表示氢，C.sub.1-C.sub.2烷基，烯丙基，2-丙炔基或由下列一般式表示的残基--F--R.sup.9，其中，F表示C.sub.2-C.sub.6烷基，而R.sup.9表示含氮杂环芳基残基或由下列一般式表示的氨基：##STR3## （其中，R.sup.10表示氢，C.sub.2-C.sub.4烷基或C.sub.1-C.sub.4酰基，而R.sup.11表示氢或C.sub.1-C.sub.4烷基，或R.sup.10与R.sup.11组合表示可选地含有其他杂原子的5-至7-成员环氨基。）这些化合物具有选择性的PAF-拮抗活性，非常有用作为预防和治疗PAF引起的疾病，例如各种炎症，过敏性疾病，循环系统疾病和胃肠疾病的药物。
• Novel thiazolidin-4-one derivatives and acid addition salts thereof
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0292305A1

  公开（公告）日：1988-11-23

  Thiazolidin-4-one derivatives are represented by the following general formula (I) wherein. R1 and R2 are the same or different and denote each (i) a residue represented by the general formula -A-R4 wherein, A denotes a single bond, C1-C8 alkylene, C2-C8 alkenylene, or C2-C8 alkynylene and R4 denotes hydrogen, C1-C12 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl, or C1-C6 haloalkyl, or (ii) a residue represented by the general formula wherein, B denotes a single bond or C1-C6 alkylene, R5 denotes hydrogen, C1-C6 alkyl, C2-Cs alkenyl, C3-C8 cycloalkyl, substituted silyl, or substituted or unsubstituted aryl, n and n' denote each an integer of 2 to 4, m denotes an integer of 1 to 3, and m' denotes an integer of 0 to 2; and R3 denotes hydrogen, C1-C2 alkyl, allyl, 2-propynyl, or a residue represented by (a) the general formula wherein, R6 denotes halogen, an aryl group substituted or unsubstituted by one or more hydroxy or C1-C4 alkoxy groups, or a residue represented by the general formula -D-R7 (D denotes oxygen or sulfur and R7 denotes hydrogen, C1-C4 alkyl, or Ci-C4 alkanol) and ℓ denotes an integer of 2 to 4, (b) the general formula wherein, E denotes oxygen, sulfur, imino, or C1-C4 alkylimino, Ra denotes hydrogen or C1-C4 alkyl, or -(E-R8) denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms, and k denotes an integer of 1 to 3, or (c) the general formula -F-R9 wherein, F denotes C2-C6 alkylene and R9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula (R10 denotes hydrogen, C1-C4 alkyl, or C1-C4 alkyl or R10 in combination with R11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms), with the proviso that, when R1 is hydrogen and R2 is methyl, R3 denotes hydrogen, Ci-C2 alkyl, 2-propynyl, or a residue represented by (a) the general formula wherein, R6 denotes halogen, an aryl group substituted or unsubstituted by one or more hydroxy or C1-C4 alkoxy groups, or a residue represented by the general formula -D-R7 (D denotes oxygen or sulfur and R7 denotes hydrogen, C1-C4 alkyl, or C1-C4 alkanoyl) and ℓ denotes an integer of 2 to 4, (b) the general formula wherein, E denotes oxygen, sulfur, imino, or C1-C4 alkylimino, denotes hydrogen or C1-C4 alkyl, or -(E-R8) denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms, and k denotes an integer of 1 to 3, or (c) the general formula -F-R9 wherein, F denotes C2-C6 alkylene and R9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula (R10 denotes hydrogen, C2-C4 alkyl or C1-C4 alkanoyl and R11 denotes hydrogen or C1-C4 alkyl or R10 in combination with R11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms. Since these derivatives, and acid addition salts thereof have selective PAF-antagonistic activities, these compounds are very useful as preventive and curative agents for PAF-induced diseases, for example, various kinds of inflamation, allergic diseases, circulatory diseases, and gastro-intestinal diseases.

  噻唑烷-4-酮衍生物由以下通式 (I) 表示 其中 R1 和 R2 相同或不同，并分别表示 (i) 通式-A-R4 所代表的残基 其中，A 表示单键、C1-C8 亚烷基、C2-C8 亚烯基或 C2-C8 亚炔基，R4 表示氢、C1-C12 烷基、C2-C8 亚烯基、C3-C8 环烷基或 C1-C6 卤代烷基，或 (ii) 由通式表示的残基 其中，B 表示单键或 C1-C6 亚烷基，R5 表示氢、C1-C6 烷基、C2-Cs 烯基、C3-C8 环烷基、取代的硅烷基或取代或未取代的芳基，n 和 n'分别表示 2 至 4 的整数，m 表示 1 至 3 的整数，m'表示 0 至 2 的整数；以及 R3 表示氢、C1-C2 烷基、烯丙基、2-丙炔基或由以下各项表示的残基 (a) 通式 其中，R6 表示卤素、被一个或多个羟基或 C1-C4 烷氧基取代或未取代的芳基，或通式 -D-R7 所代表的残基（D 表示氧或硫，R7 表示氢、C1-C4 烷基或 Ci-C4 烷醇），ℓ 表示 2 至 4 的整数、 (b) 通式 其中，E 表示氧、硫、亚氨基或 C1-C4 烷基亚氨基，Ra 表示氢或 C1-C4 烷基，或-(E-R8) 表示可选含有其他杂原子的 5 至 7 元环状氨基，且 k 表示 1 至 3 的整数，或 (c) 通式-F-R9 其中，F 表示 C2-C6 亚烷基，R9 表示含氮杂环芳香残基或由通式表示的氨基 (R10表示氢、C1-C4 烷基或 C1-C4 烷基，或 R10 与 R11 结合表示可选择含有其他杂原子的 5 至 7 元环状氨基)，但条件是，当 R1 为氢且 R2为甲基时，R3表示氢、Ci-C2烷基、2-丙炔基或由以下各项代表的残基 (a) 通式 其中，R6 表示卤素，被一个或多个羟基或 C1-C4 烷氧基取代或未取代的芳基，或通式 -D-R7 所代表的残基（D 表示氧或硫，R7 表示氢、C1-C4 烷基或 C1-C4 烷酰基），ℓ 表示 2 至 4 的整数、 (b) 通式 其中，E 表示氧、硫、亚氨基或 C1-C4 烷基亚氨基，表示氢或 C1-C4 烷基，或-(E-R8)表示可选含有其他杂原子的 5 至 7 元环氨基，且 k 表示 1 至 3 的整数，或 (c) 通式-F-R9 其中，F 表示 C2-C6 亚烷基，R9 表示含氮杂环芳香残基或通式-F-R9 所代表的氨基。 (R10 表示氢、C2-C4 烷基或 C1-C4 烷酰基，R11 表示氢或 C1-C4 烷基，或 R10 与 R11 结合表示 5 至 7 元环状氨基，该氨基可选择含有其他杂原子。 由于这些衍生物及其酸加成盐具有选择性 PAF 拮抗活性，因此这些化合物作为 PAF 引起的疾病（例如各种炎症、过敏性疾病、循环系统疾病和胃肠道疾病）的预防和治疗药物非常有用。
• 2-Pyridyl thiazolidin-4-one derivatives as anti-ulcer agents
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0325496A1

  公开（公告）日：1989-07-26

  A 2-pyridyl-thiazolidin-4-one derivative represented by the formula: wherein Ri and R2 are each a hydrogen atom, a C1-C20 alkyl group, a C2-C2o alkenyl group, a C2-C20 alkynyl group, an aryl group, a C3-C8 cycloalkyl group or an aralkyl group which may have a substituent, Rs is a hydrogen atom, a C1-C20 alkyl group, a C2-C20 alkenyl group, a C2-C2o alkynyl group, a C3-C8 cycloalkyl group or an aralkyl group which may have a substituent, P is a pyridyl group or its N-substituted pyridinium salt which may have a substituent, said substituent being selected from the group consisting of halogen atom, cyano group, hydroxy group, amino group, lower alkyl group, lower alkoxy group, lower alkylamino group, halogenated lower alkyl group, acyl group, acyloxy group, acylthio group, acylamino group, carboxyl group, lower alkoxycarbonyl group, carbamoyl group, lower alkyl substituted carbamoyl group, heterocyclic group, and lower cycloalkyl group, and n represents an integer of 0, 1 or 2, or a pharmaceutically acceptable salt thereof is an anti-ulcer agent effective against stress induced ulcers. Some of these compounds are novel.

  一种2-吡啶基噻唑烷-4-酮衍生物，由式表示： 其中 Ri 和 R2 各为氢原子、C1-C20 烷基、C2-C2o 烯基、C2-C20 炔基、芳基、C3-C8 环烷基或可带有取代基的芳烷基，Rs 为氢原子、C1-C20 烷基、C2-C20 烯基、C2-C2o 炔基、C3-C8 环烷基或可带有取代基的芳烷基、C2-C2o 烷基、C3-C8 环烷基或可带有取代基的芳基，P 是吡啶基或其 N-取代的吡啶鎓盐，可带有取代基，所述取代基可选 自卤素原子组成的组、氰基、羟基、氨基、低级烷基、低级烷氧基、低级烷基氨基、卤代低级烷基、酰基、酰氧基、酰硫基、酰氨基、羧基、低级烷氧基羰基、氨基甲酰基、低级烷基取代的氨基甲酰基、杂环基和低级环烷基，且 n 代表 0、1 或 2 的整数，或其药学上可接受的盐。其中一些化合物是新型的。
• US4992455A
  申请人：——

  公开号：US4992455A

  公开（公告）日：1991-02-12